Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - methyldopa - tablets - 250 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - methyldopa - tablets - 500 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 99.191 mg - tablet - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 66.127 mg - tablet - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 33.064 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - cinacalcet hydrochloride, quantity: 99.18 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; carnauba wax; crospovidone; povidone; colloidal anhydrous silica; hypromellose; macrogol 400; titanium dioxide; lactose monohydrate; indigo carmine; triacetin; iron oxide yellow - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). sensipar should be used as adjunctive therapy. sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. sensipar may be used to treat the biochemical manifestations of primary hyperparathryoidism in patients for whom parathryoidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - cinacalcet hydrochloride, quantity: 66.12 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; carnauba wax; magnesium stearate; microcrystalline cellulose; crospovidone; povidone; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; triacetin; iron oxide yellow; macrogol 400 - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). sensipar should be used as adjunctive therapy. sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. sensipar may be used to treat the biochemical manifestations of primary hyperparathryoidism in patients for whom parathryoidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - cinacalcet hydrochloride, quantity: 33.06 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: carnauba wax; povidone; pregelatinised maize starch; magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; triacetin; iron oxide yellow; macrogol 400 - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. sensipar should be used as adjunctive therapy. sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. sensipar may be used to treat the biochemical manifestations of primary hyperparathryoidism in patients for whom parathryoidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 33 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 99 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hyprolose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.